Morgan Stanley
UNCY icon

Morgan Stanley’s Unicycive Therapeutics UNCY Stock Holding History

Morgan Stanley’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$514K Sell
109,645
-78,537
-42% -$579K ﹤0.01% 5541
2026
Q1 		$1.24M Buy
188,182
+141,598
+304% +$928K ﹤0.01% 5030
2025
Q4 		$269K Buy
46,584
+35,972
+339% +$192K ﹤0.01% 5807
2025
Q3 		$46.3K Buy
10,612
+9,612
+961% +$41.9K ﹤0.01% 6432
2025
Q2 		$4.77K Sell
1,000
-1,227
-55% -$7.59K ﹤0.01% 7045
2025
Q1 		$12.8K Buy
2,227
+1,727
+345% +$10.5K ﹤0.01% 6730
2024
Q4 		$3.97K Buy
+500
New +$2.77K ﹤0.01% 7066
2022
Q1 		– Hold
0
– – – 8124
2021
Q4 		– Hold
0
– – – 8113

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Morgan Stanley's UNCY Position: Q2 2026 in Review

Morgan Stanley reduced its Unicycive Therapeutics (UNCY) stake by 42% in Q2 2026, selling an estimated $579K and leaving 109,645 shares worth $514K. The position accounts for ﹤0.01% of the portfolio, ranked #5541.

Morgan Stanley first reported a position in UNCY in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.24M in Q1 2026. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Morgan Stanley held 109,645 shares of Unicycive Therapeutics worth $514K as of Q2 2026.
  • Morgan Stanley sold 78,537 Unicycive Therapeutics shares in Q2 2026, an estimated $579K.
  • Unicycive Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5541 holding.
  • Morgan Stanley first reported a position in Unicycive Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Morgan Stanley's Unicycive Therapeutics position peaked at $1.24M in Q1 2026.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.